During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

In part 2 of our interview with Surbhi Sidana, MD, MBBS, American Society of Hematology and Stanford University, she delves ...

Darzalex will now be available to patients with newly diagnosed multiple myeloma eligible for autologous stem cell transplant ...

Charley Steiner's multiple myeloma is in remission, marking a significant milestone in his private cancer journey. Jack Jones ...

Revlimid (lenalidomide) is a brand-name oral capsule prescribed to treat multiple myeloma and certain other blood cell cancers in adults. This article covers topics such as side effects ...

Publication shows that OGM can resolve translocation partners involving MYC in multiple myeloma (MM) more effectively than current methodsThe ...

Explore a discovery from researchers that could one day help tailor immunotherapy treatments for patients with multiple ...

Sarclisa in combination with the VRd regiment was superior to VRd alone in improving survival in stem cell transplant ...

In separate, live virtual events, Doris Hansen, MD, and Leyla O. Shune, MD, discuss options for a patient with ...

Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a biotech company developing the industry's leading telomere technology platform with diagnostic and prognostic applications ...

This study explored the safety and efficacy of a CXCR2 agonist and plerixafor for mobilization of HSCs for hematopoietic stem cell transplantation in patients with MM.

An online survey-based cross-sectional study assessed current practice patterns on the management of post-CAR-T failure in patients with relapsed or refractory multiple myeloma.